Cerebral palsy, cognitive impairment, and sensory disabilities remain among the most consequential outcomes of complicated births — yet two interventions have now accumulated sufficient evidence to be considered standard-of-care tools for reducing these risks. Understanding what separates evidence-based neuroprotection from experimental approaches matters for families, clinicians, and anyone tracking the frontier of early-life brain health.
This review in Clinics in Perinatology consolidates the clinical evidence behind three interventions: antepartum magnesium sulfate (MgSO4) administered before anticipated preterm delivery, delayed umbilical cord clamping, and therapeutic hypothermia (controlled whole-body or selective head cooling). Antepartum MgSO4 has demonstrated reductions in the composite risk of death, cerebral palsy, and major neurodevelopmental disorders in preterm cohorts. Therapeutic hypothermia — typically initiated within six hours of birth and maintained at 33–34°C for 72 hours — targets the secondary neuronal injury cascade following hypoxic-ischemic encephalopathy (HIE) in term and late-preterm neonates, a window during which cell death is still partially reversible.
What makes this synthesis particularly valuable is the stratification by gestational age and mechanism of injury — two variables that have historically blurred clinical decision-making. MgSO4's neuroprotective mechanism is thought to involve NMDA receptor antagonism and anti-inflammatory effects, though precise dose optimization and ideal timing windows remain areas of active investigation. Therapeutic hypothermia, meanwhile, is the rare neonatal intervention with robust randomized trial backing, yet its benefits appear to diminish or become uncertain in low-resource settings where initiation delays are common. Delayed cord clamping, while included as a proven strategy, carries the least mechanistic depth in this review. Taken together, these three tools represent incrementally well-confirmed rather than paradigm-shifting science — their combined clinical adoption profile is what this review advances most meaningfully.